Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Update

Alzamend Neuro, Inc. (NASDAQ:ALZN) saw a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 358,600 shares, an increase of 196.6% from the March 15th total of 120,900 shares. Based on an average trading volume of 365,200 shares, the days-to-cover ratio is presently 1.0 days. Approximately 5.7% of the shares of the company are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Alzamend Neuro stock. Geode Capital Management LLC acquired a new stake in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 33,540 shares of the company’s stock, valued at approximately $39,000. Geode Capital Management LLC owned about 0.62% of Alzamend Neuro as of its most recent SEC filing. 49.61% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Ascendiant Capital Markets lowered their price objective on shares of Alzamend Neuro from $32.00 to $20.00 and set a “buy” rating on the stock in a research note on Monday, March 17th.

Alzamend Neuro Stock Down 6.6 %

Shares of NASDAQ:ALZN opened at $0.71 on Thursday. The firm’s 50 day simple moving average is $0.90 and its two-hundred day simple moving average is $1.19. Alzamend Neuro has a 1-year low of $0.64 and a 1-year high of $15.06.

Alzamend Neuro (NASDAQ:ALZN) last issued its earnings results on Monday, March 10th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.10. On average, sell-side analysts anticipate that Alzamend Neuro will post -1.68 EPS for the current fiscal year.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.